BBLG

Business Context and Reporting Period

Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The lead product, NB1, is currently in a pilot clinical study in Australia. The company has no significant operating history and has incurred accumulated losses of approximately $86.8 million since inception.

Key Financial Metrics

Note: Per share data has been retroactively adjusted for a 1-for-6 reverse stock split effective June 10, 2025.

Material Changes vs. Prior Period

• Capital Raise: In June 2025, the company completed a public offering raising net proceeds of approximately $4.35 million through the sale of common stock, pre-funded warrants, and Series D and E warrants. This significantly increased cash reserves from $3.3 million at year-end 2024 to $6.6 million.
• Operating Expenses: Total operating expenses increased by 4.28% year-over-year for the six-month period. Research and Development (R&D) expenses rose slightly to $615,186 (from $596,067), while General and Administrative (G&A) expenses increased to $1.17 million (from $1.12 million), largely due to the timing of stock option grants to directors.
• Warrant Liability: The change in fair value of warrant liability decreased significantly from an expense of $48,096 in the prior year period to $2,257 in the current period.
• Reverse Stock Split: A 1-for-6 reverse stock split was executed in June 2025 to regain compliance with Nasdaq listing requirements.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management states that available cash is expected to fund operations into the second quarter of 2026. However, the company has incurred substantial accumulated losses and raised substantial doubt about its ability to continue as a going concern within one year. Future financing is required to meet operational needs.
• Clinical Progress: The company is conducting a pilot clinical study for its NB1 bone graft device in Australia. The study design was reviewed by the FDA to support progression to a pivotal trial in the U.S.
• Risks: Key risks include the inability to raise additional capital, potential failure of clinical trials, regulatory hurdles (FDA PMA approval required), and reliance on third-party manufacturers. Macroeconomic factors such as inflation and interest rates also pose risks to financing availability.
• Commitments: The company has an exclusive license agreement with UCLA TDG involving milestone payments (up to $1 million upon first commercial sale) and royalties. Estimated remaining commitments under R&D agreements are approximately $268,105.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection that current cash ($6.6M) will sustain operations only until Q2 2026 given the estimated $6.8M annual burn rate.
• Dilution Impact: Review the terms of the June 2025 offering, including the 2.5 million new warrants issued and the reverse stock split, to assess potential future dilution.
• Clinical Trial Status: Confirm the enrollment status and preliminary safety data of the NB1 pilot study in Australia.
• Going Concern Status: Monitor for any additional financing announcements or restructuring efforts required to address the "substantial doubt" expressed by auditors.
• UCLA Milestones: Track progress toward the next milestone payment ($250,000) triggered by the enrollment of the first subject in a Pivotal Study.